NCT01157858View on ClinicalTrials.gov

Everolimus and LongActing Octreotide Trial in Polycystic Livers

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Polycystic Liver Disease
Interventions
DRUG

Everolimus

2.5 mg every day orally

DRUG

Octreotide LAR

40 mg every 28 days IM

Trial Locations (1)

6500 HB

Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, Nijmegen

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Radboud University Medical Center

OTHER